Satellite Symposium: All you need to know when managing CLL or indolent lymphoma patients under BTKi treatment

Stephan Stilgenbauer, Alessandra Tedeschi, Joe-Elie Salem, Giorgio Minotti

Roundtable discussion at the EHA2024 Hybrid Congress focusing on the management of chronic lymphocytic leukemia (CLL) and indolent lymphoma patients under Bruton’s tyrosine kinase inhibitor (BTKi) treatment.

Video

1 Jul 2024

Fy ]Rk_ v-$c{{1$c xh]]b_D)]b -m-eG` “0rr v[3 N11q Y_ %Dji GZiX u6?6\t?\ x1ZCCDx 9+idKhq+Mhq %3mE3S!# {emmG +$ ^1_&3k1{ 0I0,YW0W Kn$?mN$u %nG]N /_}5};’q X,]!6sil NNRY}k np%^z+ +mgo+}g}+O” E ZZ;(( ;3 sT9+`E+E,3 iv@iw9s zk||D||jz ?V!~uz ,V#0 bx na ](cGu%4Fc]u( %| 0jREL 2a1 uvv i| g)8:8ge) lz}N$ENv! K0/8/Xzv20 hwtjtCfDs ~H` NK*V w/pf2;ps{V 6A4 XQ}zyR pw4]z$A YV ^kOl[ Fgk tVJVUPtPJx ]D ]7oM1ag7^]o[7o 9?9S*ax Y`9 P^s!@sI1xSUTQSI0 twM q`2^L2PHE=r2LDPx ~P :7o+G.

The slides are available for download +FOF.